Thymosin Alpha-1 Trial for Recurrent Implantation Failure Recruiting

A clinical trial evaluating thymosin alpha-1 for recurrent implantation failure was listed as recruiting as of June 30, 2026. The study, titled "Thymosin-α1 for Recurrent Implantation Failure," is registered under identifier NCT07675980 on ClinicalTrials.gov. It is designated as a combined Phase 2/Phase 3 trial. The current status of the trial is recruiting, meaning enrollment of participants is underway or open. No results have been posted for this study according to the available record. Thymosin alpha-1 remains classified as an unapproved research compound, and this trial update does not represent an approval or a completed outcome. The listing provides only administrative details such as the trial title, phase, and recruitment status at this time. No efficacy or safety findings are included in this update, and none should be assumed based solely on the trial's existence or its current phase. Readers interested in the background and research context of thymosin alpha-1 can consult the compound overview for additional information.